Medikra is a clinical-stage biopharmaceutical company based in Malaysia that develops pharmaceutical-grade therapeutics derived from plant-based sources. The core concept is to take traditional medicinal plants native to Malaysia and Southeast Asia, standardize their bioactive compounds using pharmaceutical-grade processes, and advance them through formal clinical trials toward drug approval. Medikra's lead program is SKF7®, a standardized extract of Labisia pumila (known locally as Kacip Fatimah), currently in development as a potential treatment for abdominal obesity and metabolic syndrome, with Phase I and Phase II trials completed across India, Malaysia, and Indonesia. Its second pipeline asset, KPH1™, is a standardized extract of Kaempferia parviflora being developed for ischemic heart disease and cardiovascular aging. Medikra operates a dual-track model: a near-term nutraceutical business selling consumer health supplements in Malaysia through clinics, pharmacies, and online channels, and a long-term pharmaceutical pathway that requires substantial upfront investment with no revenue until a drug is approved. SKF7® holds FDA New Dietary Ingredient acceptance and European Novel Food authorization, enabling supplement sales in those markets ahead of any drug approval. Medikra has historically relied on Malaysian government grants and founder equity to fund R&D, has never been sustainably profitable, and is preparing for a Nasdaq IPO. IPO proceeds are planned for clinical advancement, manufacturing scale-up, and global commercialization.